REG - Allergy Therapeutics - PDMR dealing and Total Voting Rights

Allergy TherapeuticsAnnouncement

13/12/2023 17:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231213:nRSM6930Wa&default-theme=true

RNS Number : 6930W  Allergy Therapeutics PLC  13 December 2023

 

 

Allergy Therapeutics plc

("Allergy Therapeutics", or the "Company")

 

Exercise of Options, PDMR dealing and Total Voting Rights

 

 

13 December 2023 Allergy Therapeutics plc (AIM: AGY), the integrated
commercial biotechnology company specialising in allergy vaccines, announces
that, further to his intention outlined in the mandatory offer document
published on 19 October 2023, Manuel Llobet, Chief Executive Officer of the
Company, exercised options over 1,676,200 ordinary shares ("Ordinary Shares")
in the Company on 16 November 2023, which were granted at nominal value
pursuant to the Company's 2013 Long Term Incentive Plan. The Ordinary Shares
were issued and subsequently admitted to trading on 1 December 2023 pursuant
to the Company's block admission facility.

 

Following the option exercise, Manuel Llobet holds 5,001,200 Ordinary Shares
in the Company, representing approximately 0.10% of the issued share capital
of the Company.

 

Pursuant to the Company's block admission facility, the Company also issued
888,967 Ordinary Shares in satisfaction of the exercise of share options by
certain other current and former employees. These Ordinary Shares were also
admitted to trading on 1 December 2023. The share options were exercised prior
to or on 16 November 2023 as a result of the recent equity financing that
constituted a change of control for the purposes of the Company's Long Term
Share Incentive Plan. Any options not exercised by 16 November 2023 have
lapsed.

 

The new Ordinary Shares rank pari passu with the Company's existing shares.

 

Total Voting Rights

 

In accordance with DTR 5.6.1 of the Financial Conduct Authority's Disclosure
Guidance and Transparency Rules, as at 13 December 2023, the Company has
4,766,439,938 Ordinary Shares in issue. There are no shares held in treasury.
The total number of voting rights in the Company is therefore 4,766,439,938.

 

The above figure of 4,766,439,938 may be used by shareholders in the Company
as the denominator for the calculations by which they will determine if they
are required to notify their interest in, or a change in their interest in,
the share capital of the Company under the FCA's Disclosure Guidance and
Transparency Rules.

 

- ENDS -

 

 

For further information, please contact:

 

Allergy Therapeutics

Manuel Llobet, Chief Executive Officer

Shaun Furlong, Chief Financial Officer

+44 (0)1903 845 820

 

Panmure Gordon

Emma Earl, Mark Rogers, Freddy Crossley, Corporate Finance

Rupert Dearden, Corporate Broking

+44 (0) 20 7886 2500

 

ICR Consilium

Mary-Jane Elliott / David Daley / Davide Salvi

+44 20 3709 5700

allergytherapeutics@consilium-comms.com
(mailto:allergytherapeutics@consilium-comms.com)

 

Notes for editors:

 

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company,
headquartered in the UK, focussed on the treatment and diagnosis of allergic
disorders, including aluminium free immunotherapy vaccines that have the
potential to cure disease. The Group sells proprietary and third-party
products from its subsidiaries in nine major European countries and via
distribution agreements in an additional ten countries. Its broad pipeline of
products in clinical development includes vaccines for grass, tree, house dust
mite and peanut. For more information, please see www.allergytherapeutics.com
(http://www.allergytherapeutics.com) .

 

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them:

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Manuel Llobet

 2    Reason for the notification

 a)   Position/status                                              Person Discharging Managerial Responsibilities (PDMR) - Chief Executive

                                                                 Officer

 b)   Initial notification /Amendment                              Initial Notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         Allergy Therapeutics plc

 b)   LEI                                                          213800PQ7AHK7KGVOE23

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Options over ordinary shares of £0.001 each

      Identification code                                          ISIN: GB00B02LCQ05

 b)   Nature of the transaction                                    Exercise of options

 c)   Price(s) and volume(s)                                       Volume: 1,676,200

                                                                   Exercise price: £0.001
 d)   Aggregated information                                       N/A

 e)   Date of the transaction                                      16 November 2023

 f)   Place of the transaction                                     Outside of a trading venue

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHBLBDDUDBDGXX